Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
163.58 x 2 170.68 x 1
Post-market by (Cboe BZX)
165.05 +6.90 (+4.36%) 04/17/25 [NASDAQ]
163.58 x 2 170.68 x 1
Post-market 165.05 unch (unch) 16:07 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
155.65
Day High
165.42
Open 158.76
Previous Close 158.15 158.15
Volume 629,200 629,200
Avg Vol 505,900 505,900
Stochastic %K 91.34% 91.34%
Weighted Alpha +20.36 +20.36
5-Day Change +21.72 (+15.15%) +21.72 (+15.15%)
52-Week Range 111.09 - 169.37 111.09 - 169.37
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,063,264
  • Shares Outstanding, K 60,971
  • Annual Sales, $ 393,500 K
  • Annual Income, $ -409,120 K
  • EBIT $ -302 M
  • EBITDA $ -282 M
  • 60-Month Beta 0.54
  • Price/Sales 24.50
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 58.00% ( -2.17%)
  • Historical Volatility 53.33%
  • IV Percentile 75%
  • IV Rank 38.78%
  • IV High 104.10% on 04/26/24
  • IV Low 28.80% on 09/23/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 190
  • Volume Avg (30-Day) 77
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 6,901
  • Open Int (30-Day) 6,814

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.56
  • Number of Estimates 8
  • High Estimate -1.11
  • Low Estimate -1.84
  • Prior Year -2.48
  • Growth Rate Est. (year over year) +37.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
124.06 +33.04%
on 04/09/25
Period Open: 168.84
169.00 -2.34%
on 03/24/25
-3.79 (-2.24%)
since 03/17/25
3-Month
118.03 +39.84%
on 02/12/25
Period Open: 128.13
169.37 -2.55%
on 03/17/25
+36.92 (+28.81%)
since 01/17/25
52-Week
111.09 +48.57%
on 09/12/24
Period Open: 142.17
169.37 -2.55%
on 03/17/25
+22.88 (+16.09%)
since 04/17/24

Most Recent Stories

More News
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

ASND : 165.05 (+4.36%)
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

ASND : 165.05 (+4.36%)
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

TCAF : 30.49 (-0.55%)
ASND : 165.05 (+4.36%)
IBB : 118.29 (+0.42%)
HRTS : 27.69 (+1.02%)
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

ASND : 165.05 (+4.36%)
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

ASND : 165.05 (+4.36%)
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

ASND : 165.05 (+4.36%)
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

ASND : 165.05 (+4.36%)
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

ASND : 165.05 (+4.36%)
Ascendis Pharma A/S Announces U.S. Commercial Availability of YORVIPATH® for Hypoparathyroidism Treatment

Ascendis Pharma announces YORVIPATH's FDA approval and availability for treating adult hypoparathyroidism in the U.S.Quiver AI SummaryAscendis Pharma A/S has announced that its medication YORVIPATH® (palopegteriparatide),...

ASND : 165.05 (+4.36%)
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

ASND : 165.05 (+4.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 178.20
2nd Resistance Point 171.81
1st Resistance Point 168.43
Last Price 165.05
1st Support Level 158.66
2nd Support Level 152.27
3rd Support Level 148.89

See More

52-Week High 169.37
Last Price 165.05
Fibonacci 61.8% 147.11
Fibonacci 50% 140.23
Fibonacci 38.2% 133.35
52-Week Low 111.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro